Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.

Neuro-oncology - 29 Nov 2017

DeWitt John C, Jordan Justin T, Frosch Matthew P, Samore Wesley R, Iafrate A John, Louis David N, Lennerz Jochen K

Abstract excerpt

BACKGROUND: Due to the decreasing prevalence of IDH1 mutations in older patients, the 2016 World Health Organization (WHO) classification of brain tumors proposed not to perform sequencing for isocitrate dehydrogenase (IDH) in glioblastoma patients ≥55 years old. We present a cost-effectiveness analysis to estimate the financial impact of these guidelines. METHODS: From 2010 to 2015 we performed 1023 IDH tests in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Central Nervous System Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Follow-Up Studies

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Prognosis

Share to World Health Organization

Source

Open in PubMed Open full text

Identifiers

PMID: 29016871
DOI: 10.1093/neuonc/nox120
PMCID: PMC5716163

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.PMID 29016871Read ↗

Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.Semantic proximity Read ↗

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.Semantic proximity Read ↗

IDH mutations in older patients with diffuse astrocytic gliomas.Semantic proximity Read ↗

Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.Semantic proximity Read ↗

Expanding the spectrum of IDH1 mutations in gliomas.Semantic proximity Read ↗

Treatment and outcomes of IDH1-mutant gliomas in elderly patients.Semantic proximity Read ↗

The clinical use of IDH1 and IDH2 mutations in gliomasSemantic proximity Read ↗

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain ReactionSemantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Low-Grade Gliomas Correlate With Prolonged Overall Survival in Older Patients.Semantic proximity Read ↗

Clinical and Molecular Features of Patients with Gliomas Harboring Idh1 Non-Canonical Mutations: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnosticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.